Retreatment with PARPi following stem cell transplant in a patient with recurrent ovarian cancer and myelodysplastic syndrome

Objective: As the use of poly(adenosine diphosphate–ribose) polymerase inhibitors (PARPi) increases in the management of advanced ovarian cancer, therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) may be observed more frequently. Strategies for management of this unique...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shilpa Mokshagundam, Mrinal M. Patnaik, Luigi A. DeVitis, Simrit K. Warring, Megan E. Grudem, Matthew S. Block
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-08-01
coleção:	Gynecologic Oncology Reports
Assuntos:	PARP inhibitor Myelodysplastic syndrome Clonal hematopoiesis Stem cell transplantation
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2352578925001316
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!